Backloading Deal Value for Profitability in Biotech Deals?
Executive Summary
Upfront payments for approved products far exceed those in earlier-stage deals, as biotechs have the leverage to demand higher upfronts--but should they demand high upfronts, if reaching profitability is the goal?